Latest & greatest articles for zolpidem

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on zolpidem or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on zolpidem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for zolpidem

1. Zolpidem

Zolpidem Top results for zolpidem - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for zolpidem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis

Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis 29805344 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis. 349-361 10.17179/excli2018-1140 In this study, for the first time, an electro-driven microextraction method named electromembrane extraction combined with a simple high performance liquid chromatography (...) and ultraviolet detection was developed and validated for the quantitation of zolpidem in biological samples. Parameters influencing electromembrane extraction were evaluated and optimized. The membrane consisted of 2-ethylhexanol immobilized in the pores of a hollow fiber. As a driving force, a 150 V electric field was applied to facilitate the analyte migration from the sample matrix to an acceptor solution through a supported liquid membrane. The pHs of donor and acceptor solutions were optimized to 6.0

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

3. The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People

The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People 28884784 2017 09 08 2017 09 08 1532-5415 2017 Sep 07 Journal of the American Geriatrics Society J Am Geriatr Soc The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. 10.1111/jgs.15018 To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. A retrospective cohort study using data from 2001 to 2011 from (...) the National Health Insurance Research Database. Taiwan. A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period). Zolpidem users were identified as patients who used zolpidem during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped

EvidenceUpdates2017

4. Zolpidem: risk of drowsiness and reduced driving ability

Zolpidem: risk of drowsiness and reduced driving ability Zolpidem: risk of drowsiness and reduced driving ability Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Zolpidem: risk of drowsiness and reduced driving ability From: Published: 30 May 2014 Therapeutic area: Taking zolpidem is associated with a risk of impaired driving ability the next day. Article date: May 2014 Zolpidem (Edluar, Stilnoct) is used to treat insomnia. Taking zolpidem is associated with (...) a risk of impaired driving ability the next day. To reduce this risk, advise patients: to take 10 milligrams of zolpidem at bedtime and not to take it again the same night not to drive, operate machinery, or work at heights until at least 8 hours after taking zolpidem not to take zolpidem with alcohol, illicit drugs, or other central nervous system suppressants not to drive, operate machinery or work at heights if they are still drowsy after taking Zolpidem People with liver impairment

MHRA Drug Safety Update2014

5. Zolpidem

Zolpidem USE OF ZOLPIDEM IN PREGNANCY 0344 892 0909 USE OF ZOLPIDEM IN PREGNANCY (Date of issue: November 2013 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Zolpidem is a short-acting non-benzodiazepine hypnotic agent which acts (...) on benzodiazepine receptors. It is indicated in the short-term treatment of patients with debilitating insomnia, or where insomnia is causing severe distress. There are few data available concerning the use of zolpidem in human pregnancy. These data do not currently suggest an increased risk of congenital malformation but are considered too limited to state that no risk exists. Associations between in-utero zolpidem exposure and increased risks of preterm delivery and low birth weight have been reported

UK Teratology Information Service2014

7. Intermezzo (zolpidem tartrate)

Intermezzo (zolpidem tartrate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Intermezzo (zolpidem tartrate) Company: Transcept Pharmaceuticals, Inc. Application No.: 022328 Approval Date: 11/23/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date

FDA - Drug Approval Package2011

8. Zolpidem and Uncontrollable Nocturnal Eating Binges

Zolpidem and Uncontrollable Nocturnal Eating Binges Zolpidem and Uncontrollable Nocturnal Eating Binges | Clinical Correlations Zolpidem and Uncontrollable Nocturnal Eating Binges February 24, 2010 John Cruz Faculty peer reviewed A number of studies have shown that zolpidem ( Ambien ), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating behavior among users. Sleep related eating disorder (SRED) is characterized by partial arousals (...) from sleep to ingest food, usually within the first three hours after sleep onset, occurring one to six times per night. 1 Patients describe an “automatic” inclination to eat and an inability to return to sleep unless they eat. The foods are often high in calories and ingested in massive quantities. 2 The occurrence of zolpidem-induced nocturnal eating is probably more common than currently reported. In a New York Times article 3 entitled “Study links Ambien use to unconscious food forays

Clinical Correlations2010

9. Adding zolpidem to CBT produces limited benefits in persistent insomnia

Adding zolpidem to CBT produces limited benefits in persistent insomnia Adding zolpidem to CBT produces limited benefits in persistent insomnia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding zolpidem to CBT produces limited benefits in persistent insomnia Article Text Therapeutics Adding zolpidem to CBT produces limited benefits in persistent insomnia Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Does the addition of zolpidem to cognitive behavioural therapy (CBT) improve persistent insomnia

Evidence-Based Mental Health2010

10. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age

Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age 19403468 2009 04 30 2009 05 26 2012 11 15 1098-4275 123 5 2009 May Pediatrics Pediatrics Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. e770-6 10.1542/peds.2008-2945 The goal was to evaluate the hypnotic efficacy of zolpidem (...) did not differ significantly between the zolpidem and placebo groups (-20.28 vs -21.27 minutes). However, differences favoring zolpidem were observed for the older age group in Clinical Global Impression scores at weeks 4 and 8. No next-day residual effects of treatment were associated with zolpidem, and no rebound phenomena occurred after treatment discontinuation. Central nervous system and psychiatric disorders were the most-frequent treatment-emergent adverse events (>5%) that were observed

EvidenceUpdates2009

11. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 77. 2004 Authors' objectives To provide guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Authors' conclusions 1.1 When, after due consideration of the use of nonpharmacological measures, hypnotic

Health Technology Assessment (HTA) Database.2004

12. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77) Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | Guidance and guidelines | NICE Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Technology appraisal guidance [TA77] Published date: 28 April 2004 Share Guidance on zaleplon, zolpidem and zopiclone for treating insomnia in adults. Amendments to

National Institute for Health and Clinical Excellence - Technology Appraisals2004

13. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data

Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Hajak G, Muller W E, Wittchen H U, Pittrow D, Kirch W CRD summary (...) This review of case reports of the abuse and dependence potential of zolpidem and zopiclone concluded that they are relatively safe. Patients with a history of abuse or dependence, or with psychiatric disease, are at increased risk of abuse or dependence. Methodological and reporting limitations mean that this review alone cannot provide robust evidence of the safety of these drugs. Authors' objectives To review the world literature for cases of dependence of zolpidem and zopiclone in order to identify

DARE.2003

14. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy

Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Nowell P D, Mazumdar S, Buysse D J, Dew M A, Reynolds C F, Kupfer D J Authors' objectives To assess the efficacy of benzodiazepines and zolpidem for chronic insomnia. Searching MEDLINE was searched from 1966 to 1996. Current (...) but data were extracted only for the first treatment period. Specific interventions included in the review Flurazepam, estazolam, zolpidem, triazolam, quazepam, temazepam and lorazepam. These were all compared with placebo. The median duration of treatment was 7 days (range: 4 to 35). Participants included in the review People with chronic primary insomnia, in whom psychiatric and medical conditions had been ruled out as causes of insomnia. The particpants' age ranged from 18 to 65 years old

DARE.1997

15. Zolpidem: distinct from triazolam?

Zolpidem: distinct from triazolam? Zolpidem: distinct from triazolam? Zolpidem: distinct from triazolam? Lobo B L, Greene W L Authors' objectives To compare the effectiveness and adverse effects of zolpidem with triazolam in the treatment of insomnia. Searching MEDLINE was searched from 1983 to 1996 for English language publications using the terms 'triazolam' and 'zolpidem'. Study selection Study designs of evaluations included in the review Clinical trials were included. Specific (...) interventions included in the review Zolpidem (5 to 20 mg/day) and triazolam (0.125 to 0.5 mg/day); both are short-acting sedative-hypnotics. Participants included in the review People with insomnia, including populations from general practice, psychiatric in--patients and outpatients, and the elderly. Outcomes assessed in the review Several outcomes were assessed: sleep-related outcomes such as sleep onset latency, duration and quality of sleep, number of nocturnal wakenings and nocturnal awake time

DARE.1997